PMID- 32249442
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20231110
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 76
IP  - 1
DP  - 2021 Jan
TI  - Past, present, and future of allergen immunotherapy vaccines.
PG  - 131-149
LID - 10.1111/all.14300 [doi]
AB  - Allergen-specific immunotherapy (AIT) is an allergen-specific form of treatment 
      for patients suffering from immunoglobulin E (IgE)-associated allergy; the most 
      common and important immunologically mediated hypersensitivity disease. AIT is 
      based on the administration of the disease-causing allergen with the goal to 
      induce a protective immunity consisting of allergen-specific blocking IgG 
      antibodies and alterations of the cellular immune response so that the patient 
      can tolerate allergen contact. Major advantages of AIT over all other existing 
      treatments for allergy are that AIT induces a long-lasting protection and 
      prevents the progression of disease to severe manifestations. AIT is cost 
      effective because it uses the patient s own immune system for protection and 
      potentially can be used as a preventive treatment. However, broad application of 
      AIT is limited by mainly technical issues such as the quality of allergen 
      preparations and the risk of inducing side effects which results in extremely 
      cumbersome treatment schedules reducing patient s compliance. In this article we 
      review progress in AIT made from its beginning and provide an overview of the 
      state of the art, the needs for further development, and possible technical 
      solutions available through molecular allergology. Finally, we consider visions 
      for AIT development towards prophylactic application.
CI  - (c) 2020 The Authors. Allergy published by European Academy of Allergy and Clinical 
      Immunology and John Wiley & Sons Ltd.
FAU - Dorofeeva, Yulia
AU  - Dorofeeva Y
AUID- ORCID: 0000-0001-5304-2042
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Shilovskiy, Igor
AU  - Shilovskiy I
AUID- ORCID: 0000-0001-5343-4230
AD  - National Research Center, Institute of immunology, FMBA of Russia, Moscow, 
      Russian Federation.
FAU - Tulaeva, Inna
AU  - Tulaeva I
AUID- ORCID: 0000-0002-5825-2687
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
AD  - Department of Clinical Immunology and Allergy, Laboratory of Immunopathology, 
      Sechenov First Moscow State Medical University, Moscow, Russian Federation.
FAU - Focke-Tejkl, Margarete
AU  - Focke-Tejkl M
AUID- ORCID: 0000-0003-3433-5071
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Flicker, Sabine
AU  - Flicker S
AUID- ORCID: 0000-0003-4768-8693
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Kudlay, Dmitriy
AU  - Kudlay D
AD  - National Research Center, Institute of immunology, FMBA of Russia, Moscow, 
      Russian Federation.
FAU - Khaitov, Musa
AU  - Khaitov M
AD  - National Research Center, Institute of immunology, FMBA of Russia, Moscow, 
      Russian Federation.
FAU - Karsonova, Antonina
AU  - Karsonova A
AD  - Department of Clinical Immunology and Allergy, Laboratory of Immunopathology, 
      Sechenov First Moscow State Medical University, Moscow, Russian Federation.
FAU - Riabova, Ksenja
AU  - Riabova K
AD  - Department of Clinical Immunology and Allergy, Laboratory of Immunopathology, 
      Sechenov First Moscow State Medical University, Moscow, Russian Federation.
FAU - Karaulov, Alexander
AU  - Karaulov A
AD  - Department of Clinical Immunology and Allergy, Laboratory of Immunopathology, 
      Sechenov First Moscow State Medical University, Moscow, Russian Federation.
FAU - Khanferyan, Roman
AU  - Khanferyan R
AD  - Department of Immunology and Allergy, Russian People's Friendship University, 
      Moscow, Russian Federation.
FAU - Pickl, Winfried F
AU  - Pickl WF
AUID- ORCID: 0000-0003-0430-4952
AD  - Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, 
      Medical University of Vienna, Vienna, Austria.
FAU - Wekerle, Thomas
AU  - Wekerle T
AD  - Section of Transplantation Immunology, Department of Surgery, Medical University 
      of Vienna, Vienna, Austria.
FAU - Valenta, Rudolf
AU  - Valenta R
AUID- ORCID: 0000-0001-5944-3365
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Center for Pathophysiology, Infectiology and Immunology, Medical University of 
      Vienna, Vienna, Austria.
AD  - National Research Center, Institute of immunology, FMBA of Russia, Moscow, 
      Russian Federation.
AD  - Department of Clinical Immunology and Allergy, Laboratory of Immunopathology, 
      Sechenov First Moscow State Medical University, Moscow, Russian Federation.
LA  - eng
GR  - P 29991/FWF_/Austrian Science Fund FWF/Austria
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200429
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Allergens)
RN  - 0 (Vaccines)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens
MH  - Desensitization, Immunologic
MH  - Humans
MH  - *Hypersensitivity/therapy
MH  - Immunoglobulin E
MH  - *Vaccines
PMC - PMC7818275
OTO - NOTNLM
OT  - allergen
OT  - allergen-specific immunotherapy
OT  - allergy
OT  - molecular allergy vaccines
COIS- W. Pickl holds stocks of Biomay AG and receives honoraria from Novartis and 
      Pfizer. Dr Wekerle reports personal fees from Astellas, personal fees from 
      Chiesi, personal fees from Therakos, grants from TEVA, outside the submitted 
      work. Rudolf Valenta has received research grants from Viravaxx (Vienna, Austria) 
      and serves as consultant for this company. The other authors declare that they 
      have no competing interests.
EDAT- 2020/04/07 06:00
MHDA- 2021/05/15 06:00
PMCR- 2021/01/21
CRDT- 2020/04/07 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/02/25 00:00 [revised]
PHST- 2020/03/15 00:00 [accepted]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
PHST- 2021/01/21 00:00 [pmc-release]
AID - ALL14300 [pii]
AID - 10.1111/all.14300 [doi]
PST - ppublish
SO  - Allergy. 2021 Jan;76(1):131-149. doi: 10.1111/all.14300. Epub 2020 Apr 29.